[2]
Alhamidehoballah, S.A. Spectrophotometric methods for determination of cilostazol in pure and dosage forms. Int. J. Res. Pharm. Chem., 2015, 5(1), 17-26.
[3]
Kurien, J. HPTLC determination of cilostazol in pharmaceutical dosage forms. Int. J. Adv. Res. (Indore), 2014, 2(2), 952-957.
[8]
Raman, N. V. V. S. S. Analytical quality by design approach to test method development and validation in drug substance manufacturing. J. Chem, 2015, 435129.
[10]
V, JAYESH. Simultaneous estimation of cilostazol and aspirin in synthetic mixture using hptlc method. Int. J. Chem. Sci., 2008, 6(3), 1377-1384.
[20]
William, R. Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A study in long-term effects) J. Vasc. Surg., 2008, 47(2), 330-336.
[24]
Rambabu, K.; Suresh, T. Isocratic reversed phase liquid chromatographic method validation for the determination of cilostazol in pure and formulations. Int. J. Pharm. Pharm. Res., 2015, 4(3), 180-192.
[25]
Dharmendra, D.; Karan, M.; Bhoomi, P.; Rajshree, C.M. Quantification of cilostazol and telmisartan in combination using risk profile and uncertainty contour: a contemporary validation approach. J. Chromatogr. Sep. Tech., 2015, 6, 1-8.
[27]
Gomes, M.; Traudi, K.; Simionatto, M.; Nadal, J.; Zanin, S.; Borsato, D.; Farago, P. A simple RP-HPLC/UV method for determination of cilostazol in polymeric nanoparticles suspensions: Development and validation. Lat. Am. J. Pharm., 2015, 34, 803-809.
[28]
Damor, D.; Patel, B.P.; Mittal, K.; Mashru, R.C. Simultaneous estimation of cilostazol and telmisartan using PCR, PLS, CLS and ILS. World J. Pharm. Res., 2015, 4(7), 693-709.
[30]
R. Pateland, Riddhi. A new RP-HPLC method for simultaneous estimation of telmisartanand cilostazol in synthetic mixture. Int. J. Recent Sci. Res., 2015, 6(4), 3306-3310.
[35]
Deokar, Gitanjali Development and validation of UV-spectrophotometric method for estimation of cilostazol in bulk and pharmaceutical dosage form. Int. J. Pharm. Qual. Assur., 2016, 7, 90-97.
[38]
Wassel, A.A. Electrochemical behavior and determination of Cilostazol in pure, urine and in pharmaceutical formulations. Anal. Bioanal. Electrochem., 2012, 4(2), 197-211.
[39]
Patel, J.V. Simultaneous spectrophotometric estimation of cilostazol and aspirin in synthetic mixture. Int. J. Chem. Sci., 2008, 6(1), 73-79.
[40]
Sapna, N.R.; Dedania, Z. R. Simultaneous development and validation of HPTLC method for determination of zonisamide and cilostazol in synthetic mixture. World J. Pharm. Res., 2021, 10(2), 762-771.
[41]
Kurien, J.; Jayasekhar, P. Stability indicating HPLC determination of cilostazol in pharmaceutical dosage forms. Int J Pharm Bio Sci, 2014, 5(1), 176-186.
[42]
Shah, A.B.; Zarna, D.; Jain, V.C. Development and validation of UV spectroscopic simultaneous method for zonisamide and cilostazol in synthetic mixture. Pharma Sci. Monitor, 2019, 10(3), 53-65.
[43]
Joti, J.J. Validation and optimization of a simple RP-HPLC method for determination of cilostazol in human serum. Indian J. Nov. Drug Deliv., 2011, 3(2), 143-148.
[46]
Ambekar, A.M.; Kuchekar, B.S. A validated new gradient stability-indicating lc method for the simultaneous estimation of cilostazol and aspirin in bulk and tablet formulation. Eur J Biomed Pharm Sci, 2014, 1(2), 149-164.
[47]
Nirogi, S.; Ramakrishna, V. Simultaneous quantification of cilostazol and its primary metabolite 3,4-dehydrocilostazol in human plasma by rapid liquid chromatography/tandem mass spectrometry. Anal. Bioanal. Chem., 2006, 384(3), 780-790.
[48]
Tata, P.N. The quantitative determination of cilostazol and its four metabolites in human liver microsomal incubation mixtures by high-performance liquid chromatography. J. Pharm. Biomed. Anal., 1998, 18(3), 441-451.
[49]
Fu, C.J. Simultaneous quantitative determination of cilostazol and its metabolites in human plasma by high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl., 1999, 728(2), 251-262.
[50]
Varanasi, V.S. Validated high performance liquid chromatographic method for simultaneous determination of rosiglitazone, cilostazol, and 3,4-dehydro-cilostazol in rat plasma and its application to pharmacokinetics. Arzneimittelforschung, 2008, 58(6), 288-296.
[52]
Wang, J. Gradient elution LC-ESI-MS determination of cilostazol in rat plasma and its application. Lat. Am. J. Pharm., 2012, 31(2), 240-244.
[54]
Ibrahim, F.; Sharaf El-Din, M.; El-Aziz, H.A. Selective methods for cilostazol assay in presence of its oxidative degradation product and Co formulated telmisartan application to tablet formulation. J. Chromatogr. Sep. Tech., 2016, 7(335), 2.
[56]
Maheswari, G. A review on LC-MS/MS in bioanalytical studies. World J. Pharm. Res., 2013, 2(6), 274-278.
[58]
Taleuzzaman, M. Ultra performance liquid chromatography (UPLC)-A review. Austin J. Anal. Pharm. Chem., 2015, 2, 1056.
[65]
Bhattacharya, S. Central composite design for response surface methodology and its application in pharmacy. Response surface methodology in engineering science; Intech Open, 2021.
[70]
Kumar, N.; Sangeetha, D. Analytical method development by using QbD-An emerging approach for robust analytical method development. J. Pharm. Sci. Res., 2020, 12(10), 1298-1305.